SAMSRITA LABS LIMITED

(Formerly Known as DR Habeebullah Life Sciences Limited)

Date: 06-01-2025

12

To,

1. BSE Limited	 Metropolitan Stock Exchange of India Limited
P.J. Towers, Dalal Street,	205(A), 2 nd Floor, Piramal Agastya Corporate Park, Kamani
Mumbai-400 001	Junction, LBS Road, Kurla (West), Mumbai-400 070
Scrip Code: 539267	Symbol:SAMSRITA

Sub: Outcome of Board Meeting held on 06-01-2025 under Regulation 33 and 30 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Unit: Samsrita Labs Limited (Formerly known as Dr Habeebullah Life SciencesLimited)

Dear Sir/Madam,

With reference to the subject cited above, this is to inform the Exchanges that at the meeting of the Board of Directors of Samsrita Labs Limited (formerly known as Dr Habeebullah Life Sciences Limited) held on Monday, 06-01-2025 at 03:30 p.m. at the registered office of the Company situated at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500082, Telangana, the following were considered and approved:

- 1. Un-audited financial results for the Quarter III ended 31.12.2024 (Enclosed)
- 2. Limited Review Report as per Regulation 33 of SEBI (LO&DR)Regulations, 2015 for the quarter ended on 31-12-2024 (Enclosed)

The meeting concluded at 4.30 P.M

We request you to take note of the same in your records.

Thanking you.


Yours sincerely,

For Samsrita Labs Limited (Formerly known as Dr Habeebullan Life Sciences Limited)

K. Normalize

K.N.V. Narendra Kumar Whole-time Director& CFO DIN: 09223904

Encl: as above



Digitally signed by Konagalla Naga Venkata Narendra Kumar Date: 2025.01.06 16:31:34 +05'30'

Regd.Off & Corp Off: 6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad.500082. CIN No: L85110TG1996PLC09918. Email: <u>info@drhlsl.com</u>, <u>pcproductsindia@gmail.com</u>, <u>cs@drhlsl.com</u> Contact No.9490424639, Website: www.drhlsl.com

PART							(Rs in Lakhs)
	UNAUDITED FINANCIAL RES	ULTS FOR THE QU	ARTER III AND 9 M	ONTHS ENDED 3	1ST DECEMBER , 20	24	
	Particulars		Quarter ended			ate figures	
Sr.No		3 Months ended 31-12-2024	Corresponding 3 months ended in previous year 31-12-2023	Preceding 3 months ended 30-09-2024	For current period 9 Months ended 31-12-2024	For previous	Previous Year ended 31-03-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	*			-	-	
11	Other Income	-	-			-	-
	Total Revenue (I+II)	-	-	-			
	Expenses		-				
	Purchases	-	-	-			-
	Cost of Material Consumed	-		-		-	-
	Employee benefits expense	2.76	2.76	2.76	8.28	8.29	12.5
	Depreciation and Amortisation expense	0.03	0.05	0.04	0.10	0.15	0.2
	Other Expenses	1.26	1.74	1.68	8.87	9.56	12.2
	Total Expenses	4.05	4.55	4.48	17.25	18.00	24.9
V	Profit/(Loss) from before Exceptional Items and tax						
	(I-IV)	(4.05)	(4.55)	(4.48)	(17.25)	(18.00)	(24.95
	Exceptional Items	-			+	-	-
	Profit/(Loss) before tax (V-VI)	(4.05)	(4.55)	(4.48)	(17.25)	(18.00)	(24.99
	Tax Expense:			-	-	-	-
	Current Tax	-	-	-		-	-
	Deferred Tax		-	-	-	-	-
-	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(4.05)	(4.55)	(4.48)	(17.25)	(18.00)	(24.9
K	Profit/ (Loss) from discontinuing operations						
KI I	Tax Expense of discontinuing operations						
	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)					-	
	Profit/ (Loss) for the period (IX+XII)	-			-		
	Other Comprehensive Income	(4.05)	(4.55)	(4.48)	(17.25)	(18.00)	(24.99
	All () Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss				-		
	Total Comprehensive Income for the period						
0	XIII+XIV) (Comprising Profit (loss) and Other		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
	Comprehensive Income for the Period)	(4.05)	(4.55)	(4.48)	(17.25)	(18.00)	(24.99
0	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				(27725)	(20.00)	(24.55
	l) Basic	(0.03)	(0.03)	(0.03)	(0.12)	(0.12)	(0.17
	2) Diluted	(0.03)	(0.03)	(0.03)	(0.12)	(0.12)	(0.17
1	arnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)) Basic) Diduted						
VIIIE	arnings Per Equity Share (For Continued and	-		-	-		-
e	Discontinued Operations)(Face Value INR 10/- each)						
1) Basic	(0.03)	(0.03)	(0.03)	(0.12)	(0.12)	(0.17)
2) Diluted	(0.03)	(0.03)	(0.03)	(0.12)		
IX P	aid Up Equity Share Capital (Face Value of INR 10/-	10.031	[0.03]	[0.03]	(0.12)	(0.12)	(0.17)
	er share)	1,480.87	1480.87	1,480.87	1,480.87	1,480.87	1480.87

Notes:

The Unaudited financial results for the Quarter III and 9 months period ended 31, December 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on Monday, January 6th, 2025. The Statutory Auditors have carried out the Limited Review of the Unaudited Standalone Financial Results in accordance with Regulation 33 of SEBI (LODR) Regulations, 2015).

2 The Company has only one reportable segment as per requirements of AS 108 "Operating Segments" i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.

3 The figures of the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

4 The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad Date :06/01/2025

For SAMSRITA LABS LIMITED

(Formerly Known as Dr Habeebullah Life Sciences Limited)

TA/

03

-

K. N.V.Narendra Kumar Whole-time Director & CFO (DIN 09223904)



MGR & CO CHARTERED ACCOUNTANTS

HYDERABAD OFF: Flat No: 101, Suranjana empire Estates, Dwarakapuri colony, Panjagutta, Hyderabad -500082

Independent Auditor's Review Report on unaudited Quarterly Financial results of Samsrita labs Limited (Formerly known as Dr Habeebullah Life Sciences Limited) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To, The Board of Directors, Samsrita Labs Limited.

- We have reviewed the accompanying statement of unaudited financial results of Samsrita Labs Limited ("the Company") for the quarter ended December 31,2024 and year to date results for the period April 01,2024 to December 31, 2024 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
- 2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.



BO : MUMBAI : AKT House, Plot No C1 B 4/32., Opp. Artist Village Busstand, Near Arenja Complex, Sec8, CBD Belapur, Mumbai-400614. **Email: camgr9@gmail.com** HO: BHIMAVARAM: 24-3-11/201,,Suma Sri Residency, Main Street, Sriramapuram, Bhimavaram, Andhra Pradesh-534202. Phone: +9140 6464 4418



HYDERABAD OFF: Flat No: 101, Suranjana empire Estates, Dwarakapuri colony, Panjagutta, Hyderabad -500082

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MGR & CO Chartered Accountants FRN:012787S





M.G Rao Partner M.No.029893 UDIN: 25029893BMHAER3561

Place: Hyderabad Date: 06.01.2024 B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE QUALIFIED INSTITUTIONS PLACEMENT ETC. - Not Applicable

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES - Not Applicable

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – Not Applicable.